MARKET

ACTU

ACTU

Actuate Therapeutics Inc
NASDAQ
2.985
+0.010
+0.34%
Opening 12:22 05/12 EDT
OPEN
2.860
PREV CLOSE
2.975
HIGH
3.085
LOW
2.850
VOLUME
59.37K
TURNOVER
--
52 WEEK HIGH
11.99
52 WEEK LOW
1.580
MARKET CAP
70.78M
P/E (TTM)
-2.8230
1D
5D
1M
3M
1Y
5Y
1D
Actuate Wins FDA Clearance for Oral Elraglusib Trial
TipRanks · 17h ago
Actuate Therapeutics receives FDA clearance for oral elraglusib study
TipRanks · 1d ago
Actuate Therapeutics adds Martin Huber to board of directors
PUBT · 1d ago
Actuate Therapeutics Announces FDA Clearance Of IND For Phase 1/2 Study Of Oral Elraglusib In Advanced Cancer Patients, With Focus On Metastatic Melanoma, NSCLC, Colorectal, And Pancreatic Cancers With Initiation Planned For 2H 2026
Benzinga · 1d ago
Actuate Therapeutics wins FDA IND clearance for oral elraglusib cancer trial
PUBT · 1d ago
ACTUATE THERAPEUTICS INC - FDA CLEARS IND FOR PHASE 1/2 STUDY OF ORAL ELRAGLUSIB IN ADVANCED CANCER PATIENTS
Reuters · 1d ago
Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Dow Jones · 1d ago
Press Release: Actuate Therapeutics Announces FDA -2-
Dow Jones · 1d ago
More
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Webull offers Actuate Therapeutics Inc stock information, including NASDAQ: ACTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACTU stock methods without spending real money on the virtual paper trading platform.